MRD relapse patterns
| . | MRD status . | . | |
|---|---|---|---|
| Clinical End Point . | MRD− . | MRD conversion . | P-value* . |
| (n = 344) . | (n = 224) . | ||
| No clinical relapse | 330 (95.9) | 61 (27.2) | <.0001 |
| Relapse† | 14 (4.1) | 163 (72.8) | <.0001 |
| Clinical relapse‡ | 14 (4.1) | 118 (52.7) | <.0001 |
| Biochemical relapse§ | 0 (0.0) | 45 (20.1) | <.0001 |
| . | MRD status . | . | |
|---|---|---|---|
| Clinical End Point . | MRD− . | MRD conversion . | P-value* . |
| (n = 344) . | (n = 224) . | ||
| No clinical relapse | 330 (95.9) | 61 (27.2) | <.0001 |
| Relapse† | 14 (4.1) | 163 (72.8) | <.0001 |
| Clinical relapse‡ | 14 (4.1) | 118 (52.7) | <.0001 |
| Biochemical relapse§ | 0 (0.0) | 45 (20.1) | <.0001 |
Data are numbers (%) unless otherwise noted.
P-value determined by Fisher’s exact test.
Relapse defined using IMWG criteria, reappearance of serum or urine M-protein by immunofixation or electrophoresis, development of >5% plasma cells in the BM, or appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia)14
Clinical relapse defined as relapse with any 1 of the following: >30% BM involvement, presence of focal lesion on imaging (PET-CT, MRI DWIBS), presence of CRAB criteria, presence of high-risk GEP signature at relapse, or abnormal metaphase cytogenetics due to MM.
Biochemical relapse defined as relapse with any 1 of the following: a rising M-protein or FLC, <30% BM involvement, focal lesion on imaging (PET-CT, MRI DWIBS), no CRAB criteria, no high-risk GEP signature at relapse, or no abnormal metaphase cytogenetics due to MM.